Log in

ASX:RACRace Oncology Stock Price, Forecast & News

A$0.34
-0.01 (-2.86 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.34
Now: A$0.34
A$0.37
50-Day Range
A$0.34
MA: A$0.34
A$0.34
52-Week Range
A$0.05
Now: A$0.34
A$0.87
Volume76,322 shs
Average VolumeN/A
Market Capitalization$39.30 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Race Oncology Limited operates as a specialty pharmaceutical company in Australia. It develops Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.08 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9097 1656

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$159,371.00
Cash FlowA$0.01 per share
Book ValueA$0.05 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$39.30 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RAC News and Ratings via Email

Sign-up to receive the latest news and ratings for RAC and its competitors with MarketBeat's FREE daily newsletter.

Race Oncology (ASX:RAC) Frequently Asked Questions

How has Race Oncology's stock been impacted by COVID-19 (Coronavirus)?

Race Oncology's stock was trading at A$0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RAC shares have decreased by 4.2% and is now trading at A$0.34. View which stocks have been most impacted by Coronavirus.

How were Race Oncology's earnings last quarter?

Race Oncology Ltd (ASX:RAC) released its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter. View Race Oncology's earnings history.

Has Race Oncology been receiving favorable news coverage?

Media stories about RAC stock have trended very negative this week, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Race Oncology earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Race Oncology.

Who are some of Race Oncology's key competitors?

What other stocks do shareholders of Race Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Pilbara Minerals (PLS), Mount Gibson Iron (MGX) and Mesoblast (MESO).

Who are Race Oncology's key executives?

Race Oncology's management team includes the following people:
  • Mr. Peter Laurence Molloy, MD, CEO & Director (Age 65)
  • Dr. Gordon Beck, Sr. VP of Bus. Devel.
  • Dr. Samar Al-Behaisi, Chief Medical Officer & VP of Medical Affairs
  • Mr. Peter G. Webse B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 56)

What is Race Oncology's stock symbol?

Race Oncology trades on the ASX under the ticker symbol "RAC."

What is Race Oncology's stock price today?

One share of RAC stock can currently be purchased for approximately A$0.34.

How big of a company is Race Oncology?

Race Oncology has a market capitalization of $39.30 million and generates $159,371.00 in revenue each year.

What is Race Oncology's official website?

The official website for Race Oncology is www.raceoncology.com.

How can I contact Race Oncology?

The company can be reached via phone at 61 3 9097 1656.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.